The Top Ten Global In-Vitro Diagnostics Companies: Positioning, Performance and SWOT Analyses
Scripp Business Insights, March 2009, Pages: 160
The in-vitro diagnostics (IVD) market continues to grow at a steady pace, driven by new fields such as molecular diagnostics and a growing consumer awareness surrounding disease management. There is also an increasing focus on emerging markets, where healthcare infrastructures are improving. The industry is highly competitive and continues to witness large scale consolidation. Major in-vivo players are beginning to enter the in-vitro market and the regulatory environment is becoming even more stringent, increasing the time to approval for new products.
‘The Top 10 Global In-Vitro Diagnostics Companies’ is a report that explores the global competitive landscape of the IVD industry. This report analyses the size and structure of the market and identifies the latest developments in service offerings, new technologies, strategic approaches and competitive dynamics amongst leading companies. This report assesses the opportunities and threats facing the top 10 IVD companies in the future, and examines their current structure, financial performance, growth strategies and R&D activity. Growth forecasts for key products and regions are also provided.
Key Findings
The global in-vitro diagnostics (IVD) market is forecast to grow at a rate of 6% to reach $50.0bn in 2012. The market has been growing at a rate of 5-6% in recent years, reaching a value of $36.5bn in 2007.
Roche is the largest player in the market with a share of 20%. It is followed by Siemens and Abbott, who both hold 12% of the market. The IVD market is highly consolidated, with the top ten players holding close to 80% market share.
Molecular diagnostics, diabetes care, and emerging markets are the key growth drivers of the IVD industry. Theranostics is an emerging field with great promise and a number of players are making extensive efforts in the area.
Abbott’s IVD revenues increased by 10.8% to reach $4.4bn in 2007. However, Abbott’s diagnostics margins have been falling and it has recently announced a cost-cutting plan to improve the operating margin of its diagnostics unit. Abbott has also been faced with regulatory issues, with its diagnostics business coming under FDA supervision.
A number of large in-vivo players have entered the IVD market recently, signalling the convergence of the two diagnostic fields. Siemens Healthcare is a prominent example of this trend, following their acquisition of DPC, Bayer Diagnostics and Dade Behring.
Use this report to...
- Compare the performances of the top 10 IVD companies across key business segments and geographies with this report’s analysis of Roche Diagnostics, Siemens Healthcare, Abbott, J&J, Beckman Coulter, Becton Dickinson, bioMerieux, Bayer Diabetes, Sysmex and Bio-Rad.
- Understand the market dynamics shaping the global IVD industry, forecast key growth areas by product/region and identify deal-making patterns across clinical trials phases and key therapeutic areas.
- Evaluate the future prospects of major IVD players with this report’s examination of R&D expenditure, M&A activity, growth strategies and SWOT analyses for each of the top 10
companies.
- Measure the progress of other leading IVD companies by analysing the financial performances of Inverness, Chiron (Novartis), Olympus, Gen Probe, Hologic/Cytyc, Qiagen, Arkray, DiaSorin, Radiometer, Werfen.
Explore issues including...
Industry consolidation. The IVD market is consolidating further due to a large number of smaller companies striving to increase their market share through M&A activity. Big Pharma is also entering the IVD market through acquisitions.
Growth of molecular diagnostics. Molecular diagnostics is one of the fastest growing segments of the IVD market and is expected to grow at a CAGR of 14% over the next five years.
Stringent regulatory environment. Regulation within the IVD market is becoming increasingly stringent, particularly in the US where the FDA is intensifying its scrutiny on diagnostics companies.
Emergence of theranostics. Advances in the field of genomics are leading to the emergence of theranostics and personalized healthcare. Theranostics uses diagnostic testing to tailor disease treatment to individual needs through the application of molecular diagnostics. A number of players are currently conducting R&D and launching new products in the fields of
theranostics and personalized healthcare.
Discover...
- What are the key trends and issues within the global IVD industry?
- Who are the top 10 companies in the IVD market?
- How do the leading companies compare in terms of financial performance, R&D capabilities and coverage by country and category?
- Who are the leading companies outside of the top 10?
- Which regions and segments offer the greatest growth opportunities for leading companies?
- What are the key strategies of the leading IVD companies and how do these strategies drive revenue and market share?
- What is the future outlook of the global IVD industry?
The Top Ten Global In-Vitro Diagnostics Companies
Executive summary 16
Market Development 16
Roche Diagnostics 17
Siemens Healthcare 17
Abbott 18
J&J 19
Beckman Coulter 19
Becton Dickinson 20
bioMerieux 21
Bayer Diabetes 21
Sysmex 22
Bio Rad 23
Chapter 1 Introduction 26
What is this report about? 26
Methodology and definitions 26
Chapter 2 Market development 30
Summary 30
Overview 31
Market size and growth 31
Growth drivers 31
Key trends in the market 32
Industry consolidation 32
Convergence of IVD and In-vivo 32
Customer consolidation 33
Emergence of theranostics 33
Positioning and performance of top ten players 33
Chapter 3 Roche Diagnostics 38
Summary 38
Company overview 39
Group structure 39
Professional Diagnostics 39
Diabetes Care 39
Molecular Diagnostics 40
Applied Science 40
Recent financial performance 40
Performance by business segments (IVD) 42
Professional Diagnostics 42
Diabetes Care 42
Molecular Diagnostics 42
Performance by geographies 43
Acquisitions and divestments 44
Research and Development 45
Growth strategies 45
SWOT analysis 46
Strengths 46
Dominant market position 46
Diversified portfolio 47
Strong R&D facilities 47
Weaknesses 47
Slow growth of molecular diagnostics business 47
Opportunities 47
Molecular diagnostics market 47
Diabetes care and tissue diagnostics 48
Threats 48
Competition 48
Customer consolidation 48
Stringent regulations 49
Chapter 4 Siemens Healthcare 52
Summary 52
Company overview 53
Group structure 53
Recent financial performance 54
Acquisitions and divestments 55
Research and development 55
Growth strategies 56
SWOT analysis 57
Strengths 57
Full suite of diagnostics offering 57
Strong market position 58
Strong brand name 58
Weaknesses 58
Late entry into IVD 58
Opportunities 58
Integrated offerings 58
Molecular diagnostics market 59
Threats 59
Competition 59
Regulation 59
Chapter 5 Abbott 62
Summary 62
Company overview 63
Group structure 63
Recent financial performance 64
Performance by products 65
Performance by geographies 66
Acquisitions and divestments 66
Research and development 67
Growth strategies 67
SWOT analysis 68
Strengths 68
Diversified revenue stream 68
Strong performance of international diagnostics business 69
Weaknesses 69
Declining margins 69
Regulatory issues 69
Sluggish top line growth in the domestic market 69
Opportunities 70
Molecular diagnostics 70
Diabetes care market 70
Threats 70
Competition 70
Regulatory environment 70
Chapter 6 Johnson & Johnson 72
Summary 72
Company overview 73
Group structure 73
Ortho-Clinical Diagnostics 73
Veridex 74
LifeScan 74
Recent financial performance 74
Performance by businesses 75
LifeScan 75
Ortho-Clinical Diagnostics 75
Veridex 76
Acquisitions and divestments 76
Growth strategies 77
Strategic partnerships 77
Acquisitions 77
SWOT analysis 78
Strengths 78
Strong market position 78
J&J brand 79
Strong topline growth 79
Weaknesses 79
Small contribution to J&J revenues 79
Opportunities 79
Amic acquisition 79
Diabetes monitoring market 80
Threats 80
Competition 80
Regulations 80
Chapter 7 Beckman Coulter (Beckman) 82
Summary 82
Company overview 83
Group structure 83
Clinical Diagnostics 84
Recent financial performance 84
Performance by geographies 85
Acquisitions and divestments 87
Research and Development 87
Growth strategies 88
Focus on immunoassay systems and molecular diagnostics 88
Expansion into emerging markets 89
SWOT analysis 89
Strengths 90
Global presence 90
Strong market position 90
Diverse product portfolio 90
Strong performance of immunoassay systems 90
Weaknesses 90
Late entry into molecular diagnostics 90
Lower operating margin 91
Opportunities 91
Emerging markets 91
Immunoassay systems 91
Threats 91
Consolidation of customers 91
Stiff competition 92
Chapter 8 Becton Dickinson (BD) 94
Summary 94
Company overview 95
Group structure 95
Preanalytical Systems 95
Diagnostic Systems 96
Recent financial performance 96
Performance by business segments 97
Preanalytical Systems 97
Diagnostics Systems 98
Acquisitions and divestments 98
Research and Development 98
Growth strategies 99
Strategic acquisitions 99
Organic growth measures 99
SWOT analysis 100
Strengths 101
Increased focus on Research and Development 101
Acquisition of TriPath and GeneOhm 101
Global presence 101
Weaknesses 101
Falling margins 101
Weak BGM business 101
Opportunities 102
HAI market 102
Cancer diagnostics market 102
Threats 102
Competition 102
Regulations 102
Chapter 9 bioMerieux 104
Summary 104
Company overview 105
Group structure 105
Clinical Diagnostics 105
Industrial Diagnostics 105
Recent financial performance 105
Performance by geographies 106
Acquisitions and divestments 107
Research and Development 108
Growth strategies 108
Geographic expansion 108
Infectious diseases and high-medical value tests 109
SWOT analysis 110
Strengths 110
Global presence 110
Strong R&D capabilities 111
Strong market position 111
Weaknesses 111
Weak performance of Immunoassay 111
Divestments 111
Opportunities 112
Emerging markets 112
Molecular Biology market 112
Threats 112
Competitive and pricing pressures 112
Regulatory environment 112
Chapter 10 Bayer Healthcare 114
Summary 114
Company overview 115
Group structure 115
Recent financial performance 115
Acquisitions and divestments 116
Growth strategies 117
SWOT analysis 118
Strengths 118
Strong revenue growth 118
Strong position in diabetes care market 119
Weaknesses 119
Divestment of clinical diagnostics business 119
Small size of diabetes care business within Bayer 119
Opportunities 119
Strategic acquisition and partnerships 119
Threats 120
Loss of market share 120
Chapter 11 Sysmex 122
Summary 122
Company overview 123
Group structure 123
Recent financial performance 124
Performance by product segments 125
Performance by geographies 126
Japan 126
Americas 126
Europe 126
China 126
Asia-Pacific 126
Acquisitions and divestments 128
Research and Development 128
Growth strategies 129
Strategic alliances 129
Strengthening global sales and distribution network 129
Focus on Asia 129
Expansion into life sciences 130
SWOT analysis 130
-Roche Diagnostics
-Siemens Healthcare
-Abbott
-J&J
-Beckman Coulter
-Becton Dickinson
-bioMerieux
-Bayer Diabetes
-Sysmex
-Bio Rad
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
